OLMA - Olema Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

373.3M

Cash

167.4M

Avg Qtr Burn

-20.05M

Short % of Float

10.48%

Insider Ownership

6.84%

Institutional Own.

82.83%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OP-1250 (palazestrant) (CER antagonist) Details Metastatic breast cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OP-1250 (palazestrant) +palbociclib Details Metastatic breast cancer, Breast cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OP-1250 (palazestrant) +ribociclib or alpelisib Details Breast cancer, Metastatic breast cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.